These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

707 related articles for article (PubMed ID: 20546237)

  • 41. Effect of Switching to Travoprost Preserved With SofZia in Glaucoma Patients With Chronic Superficial Punctate Keratitis While Receiving BAK-preserved Latanoprost.
    Aihara M; Ikeda Y; Mizoue S; Arakaki Y; Kita N; Kobayashi S;
    J Glaucoma; 2016 Jun; 25(6):e610-4. PubMed ID: 25967526
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Short-term tolerability of once-daily timolol hemihydrate 0.5%, timolol maleate in sorbate 0.5%, and generic timolol maleate gel-forming solution 0.5% in glaucoma and/or ocular hypertension: a prospective, randomized, double-masked, active-controlled, three-period crossover pilot study.
    Sonty S; Mundorf TK; Stewart JA; Stewart WC
    Clin Ther; 2009 Oct; 31(10):2063-71. PubMed ID: 19922877
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of the toxicity profile of benzalkonium chloride-preserved tafluprost and SofZia-preserved travoprost applied to the ocular surface.
    Kanamoto T; Kiuchi Y; Tanito M; Mizoue S; Naito T; Teranishi S; Hirooka K; Rimayanti U;
    J Ocul Pharmacol Ther; 2015 Apr; 31(3):156-64. PubMed ID: 25710276
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure.
    Rossetti L; Karabatsas CH; Topouzis F; Vetrugno M; Centofanti M; Boehm A; Viswanathan A; Vorwerk C; Goldblum D
    Ophthalmology; 2007 Dec; 114(12):2244-51. PubMed ID: 17459480
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of bimatoprost as replacement for latanoprost in patients with glaucoma or ocular hypertension: a uniocular switch study.
    Casson RJ; Liu L; Graham SL; Morgan WH; Grigg JR; Galanopoulos A; Crawford A; House PH
    J Glaucoma; 2009; 18(8):582-8. PubMed ID: 19826386
    [TBL] [Abstract][Full Text] [Related]  

  • 46. From benzalkonium chloride-preserved Latanoprost to Polyquad-preserved Travoprost: a 6-month study on ocular surface safety and tolerability.
    Rossi GC; Scudeller L; Rolle T; Pasinetti GM; Bianchi PE
    Expert Opin Drug Saf; 2015 May; 14(5):619-23. PubMed ID: 25759110
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension.
    Olander K; Zimmerman TJ; Downes N; Schoenfelder J;
    Clin Ther; 2004 Oct; 26(10):1619-29. PubMed ID: 15598478
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
    Stewart WC; Konstas AG; Nelson LA; Kruft B
    Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A comparative study of a preservative-free latanoprost cationic emulsion (Catioprost) and a BAK-preserved latanoprost solution in animal models.
    Daull P; Buggage R; Lambert G; Faure MO; Serle J; Wang RF; Garrigue JS
    J Ocul Pharmacol Ther; 2012 Oct; 28(5):515-23. PubMed ID: 22671995
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of latanoprost on the diurnal variations in the intraocular and ocular perfusion pressure in normal tension glaucoma.
    Ishibashi S; Hirose N; Tawara A; Kubota T
    J Glaucoma; 2006 Oct; 15(5):354-7. PubMed ID: 16988595
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The use of benzalkonium chloride in topical glaucoma treatment: An investigation of the efficacy and safety of benzalkonium chloride-preserved intraocular pressure-lowering eye drops and their effect on conjunctival goblet cells.
    Nagstrup AH
    Acta Ophthalmol; 2023 Dec; 101 Suppl 278():3-21. PubMed ID: 38037546
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy.
    Lewis RA; Katz GJ; Weiss MJ; Landry TA; Dickerson JE; James JE; Hua SY; Sullivan EK; Montgomery DB; Wells DT; Bergamini MV;
    J Glaucoma; 2007 Jan; 16(1):98-103. PubMed ID: 17224758
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients.
    Konstas AG; Katsimbris JM; Lallos N; Boukaras GP; Jenkins JN; Stewart WC
    Ophthalmology; 2005 Feb; 112(2):262-6. PubMed ID: 15691561
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Success rates for switching to dorzolamide/timolol fixed combination in timolol responders who are insufficiently controlled by latanoprost monotherapy.
    Sonty S; Henry JC; Sharpe ED; Weiss MJ; Stewart JA; Nelson LA; Stewart WC
    Acta Ophthalmol; 2008 Jun; 86(4):419-23. PubMed ID: 18039347
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components.
    Diestelhorst M; Larsson LI;
    Ophthalmology; 2006 Jan; 113(1):70-6. PubMed ID: 16263174
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Efficacy of pneumatic traheculoplasty (PNT) in patients with open angle glaucoma and ocular hypertension--a preliminary report].
    Wierzbowska J; Stankiewicz A; Romańska Ł
    Klin Oczna; 2008; 110(7-9):287-91. PubMed ID: 19112863
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: Results from the VISIONARY Study Population in Spain.
    Garcia-Medina JJ; Benitez-Del-Castillo J; Rodríguez-Agirretxe I; Lopez-Lopez F; Moreno-Valladares A;
    J Ocul Pharmacol Ther; 2022 Apr; 38(3):252-260. PubMed ID: 35230148
    [No Abstract]   [Full Text] [Related]  

  • 58. Ocular hypotensive effect of tafluprost in latanoprost low-responder cynomolgus monkeys.
    Kurashima H; Asai Y; Aihara M; Ishida N; Nakamura M; Araie M
    J Glaucoma; 2012 Feb; 21(2):123-8. PubMed ID: 21423041
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and safety of topical travoprost with sofzia preservative for Japanese glaucoma patients.
    Kanamoto T; Kiuchi Y; Suehiro T; Nakano T; Nakano Y; Hirota A; Miyata A
    Hiroshima J Med Sci; 2010 Dec; 59(4):71-5. PubMed ID: 21361083
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of Tafluprost compared with latanoprost.
    Traverso CE; Ropo A; Papadia M; Uusitalo H
    J Ocul Pharmacol Ther; 2010 Feb; 26(1):97-104. PubMed ID: 20148656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.